AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

In recent years successive governments have sought to close down free speech. If we are to avoid the enslavement of our ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.